Erratum: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association (American Journal of Gastroenterology (2012) 107 (811-826) DOI: 10.1038/ajg.2012.128);The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

American Journal of Gastroenterology

Volumn 107, Issue 6, 2012, Pages 811-826

  Chalasani, Naga ^a   Younossi, Zobair ^b   Lavine, Joel E ^c   Diehl, Anna Mae ^d   Brunt, Elizabeth M ^e   Cusi, Kenneth ^f   Charlton, Michael ^g   Sanyal, Arun J ^h  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Liver Disease   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d DUKE UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g MAYO CLINIC   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA TOCOPHEROL; AMIODARONE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; METHOTREXATE; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TAMOXIFEN; URSODEOXYCHOLIC ACID; VALPROIC ACID;

ABETALIPOPROTEINEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; CHILDHOOD DISEASE; DYSLIPIDEMIA; FATTY LIVER; FOOD INTAKE; HELLP SYNDROME; HEPATITIS C; HUMAN; HYPOGONADISM; HYPOPITUITARISM; HYPOTHYROIDISM; INBORN ERROR OF METABOLISM; INCIDENCE; LIFESTYLE MODIFICATION; LIPODYSTROPHY; LIVER BIOPSY; LIVER CIRRHOSIS; MEDICAL SOCIETY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PARENTERAL NUTRITION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; REYE SYNDROME; RISK FACTOR; SCREENING; SLEEP APNEA SYNDROME; STARVATION; WILSON DISEASE;

EID: 84861901590     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.217     Document Type: Erratum

References (198)

1. Eddy DM. A Manual for Assessing Health Practices and Designing Practice Guidelines. American College of Physicians: Philadelphia, 1996, 1-126.
2. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. (Pubitemid 351632017)
3. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their management. Hepatology 2009;49:306-17.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Th er 2011;34 : 274-85.
5. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-88.
6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341-50.
7. Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-49.
8. Musso G, Gambino R, Cassaderader M et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
9. Suzuki A, Angulo P, Lymp J et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005;41:64-71. (Pubitemid 40066384)
10. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005;143:722-8.
11. Whalley S, Puvanachandra P, Desai A et al. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med 2007;7:119-24. (Pubitemid 46713720)
12. Lee JY, Kim KM, Lee SG et al. Prevalence and risk factors of nonalcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007;47:239-44. (Pubitemid 47021248)
13. Marcos A, Fischer RA, Ham JM et al. Selection and out come of living donors for adult to adult right lobe transplantation. Transplantation 2000;69:2410-5. (Pubitemid 30409013)
14. Williams CD, Stenger J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-31.
15. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95. (Pubitemid 39657013)
16. Boza C, Riquelme A, Ibañez L et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005;15:1148-53. (Pubitemid 41390213)
17. Haentjens P, Massaad D, Reynaert H et al. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. Acta Clin Belg 2009;64:483-93.
18. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600-6. (Pubitemid 44307393)
19. Colicchio P, Tarantino G, del Genio F et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 2005;49:289-95. (Pubitemid 41291550)
20. Beymer C, Kowdley KV, Larson A et al. and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003;138:1240-4.
21. Leite NC, Salles GF, Araujo AL et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29:113-9.
22. Prashanth M, Ganesh HK, Vima MV et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009;57:205-10.
23. Assy N, Kaita K, Mymin D et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45:1929-34.
24. Li H, Wang YJ, Tan K et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat Dis Int 2009;8:377-82.
25. Amarapurkar D, Kamani P, Patel N et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007;6:161-3. (Pubitemid 350277193)
26. Park SH, Jeon WK, Kim SH et al. Prevalence and risk factors of nonalcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21 (1 Part 1):138-43.
27. Frith J, Day CP, Henderson E et al. Non-alcoholic fatty liver disease in older people. Gerontology 2009;55:607-13.
28. Chen CH, Huang MH, Yang JC et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007;22:1482-9. (Pubitemid 47274571)
29. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-12.
30. Hashimoto E, Yatsuji S, Kaneda H et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2005;33:72-6. (Pubitemid 41799778)
31. Adams LA, Lymp JF, St Sauver J et al. Th e natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;l:129:113-21.
32. Chen ZW, Chen LY, Dai HL et al. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B 2008;9:616-22.
33. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7. (Pubitemid 36733754)
34. Kallwitz ER, Kumar M, Aggarwal R et al. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 2008;53:1358-63.
35. Wagenknecht LE, Scherzinger AL, Stamm ER et al. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity 2009;17:1240-6.
36. Fischer GE, Bialek SP, Homan CE et al. Chronic liver disease among Alaska-Native people, 2003-2004. Am J Gastroenterol 2009;104:363-70.
37. Bialek SR, Redd JT, Lynch A et al. Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000-2003. J Clin Gastroenterol 2008;42:949-54.
38. Matteoni CA, Younossi ZM, Gramlich T et al. fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9. (Pubitemid 29258890)
39. Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-5. (Pubitemid 38561456)
40. Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73. (Pubitemid 46489550)
41. Dunn W, Xu R, Wingard D et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103:2263-71.
42. Rafiq N, Bai CH, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastro Hepatol 2009;7:234-8.
43. Dam-Larsen S, Becker U, Franzmann MB et al. Final results of a longterm, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009;44:1236-43.
44. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome as independent predictors of mortality in chronic liver disease: a population- based study. Gut 2010;59:1410-5.
45. Söderberg C, Stå lP, Askling J et al. Survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51: 595-602.
46. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004;40:578-84. (Pubitemid 38367778)
47. Browning JD, Kumar KS, Saboorian MH et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004;99:292-8. (Pubitemid 38279872)
48. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. (Pubitemid 34747534)
49. Hashimoto E, Yatsuji S, Tobari M et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009;44:89-95.
50. Smedile A, Bugianesi E. Steatosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci 2005;9:291-3. (Pubitemid 41387394)
51. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010;16:1436-41.
52. Ascha MS, Hanouneh IA, Lopez R et al. The incidence and risk factor of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
53. Yasui K, Hashimoto E, Komorizono Y et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428-33.
54. Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7. (Pubitemid 36919863)
55. Sanyal AJ, Banas C, Sargeant C et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;42:132-8.
56. Yatsuji S, Hashimoto E, Tobari M et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-54.
57. Bhala N, Angulo P, van der Poorten D et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis. An International Collaborative Study. Hepatology 2011;54:1208-16.
58. Sanyal AJ, Brunt EM, Kleiner DE et al. End points and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53.
59. Liagnpunsakul S, Chalasani N. What do we recommend our patients with NAFLD about alcohol consumption? Am J Gastroenterol 2012 (in press).
60. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108:9-13. (Pubitemid 30058272)
61. Willner IR, Walters B, Patil SR et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61. (Pubitemid 32959539)
62. Abdelmalek MF, Liu C, Shuster J et al. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:1162-9. (Pubitemid 44311647)
63. Schwimmer JB, Celedon MA, Lavine JE et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136:1585-92.
64. Kowdley KV. The role of iron in nonalcoholic fatty liver disease: the story continues. Gastroenterology 2010;138:817-9.
65. Bacon BR, Adams PC, Kowdley KV et al. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328-43.
66. Vuppalanchi R, Gould RJ, Wilson LA et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2011 (e-pub ahead of print).
67. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23. (Pubitemid 36397405)
68. Kang H, Greenson JK, Omo JT et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006;101:2247-53. (Pubitemid 44477551)
69. Ryan MC, Wilson AM, Slavin J et al. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005;28:1222-4. (Pubitemid 40616643)
70. Wieckowska A, Zein NN, Yerian LM et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33. (Pubitemid 44049136)
71. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54. (Pubitemid 46631552)
72. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007;46:582-9. (Pubitemid 47344794)
73. Andersen T, Gluud C, Franzmann MB et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-9.
74. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-13. (Pubitemid 20381878)
75. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995;10:414-21.
76. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7. (Pubitemid 27357062)
77. Kugelmas M, Hill DB, Vivian B et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-9. (Pubitemid 36919862)
78. Sreenivasa Baba CS, Alexander G, Kalyani B et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006;21:191-8.
79. Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-9. (Pubitemid 38241340)
80. Suzuki A, Lindor K, Saver J et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatology 2005;43:1060-6. (Pubitemid 41627993)
81. Tiikkainen M, Bergholm R, Vehkavaara S et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003;52:701-7. (Pubitemid 36323577)
82. Tamura Y, Tanaka Y, Sato F et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005;90:3191-6. (Pubitemid 41014274)
83. Westerbacka J, Lammi K, Hakkinen AM et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90:2804-9. (Pubitemid 40686327)
84. Petersen KF, Dufour S, Befroy D et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54: 603-8. (Pubitemid 40322060)
85. Larson-Meyer DE, Heilbronn LK, Redman LM et al. Effect of calorie restriction with or without exercise on insulin sensitivity, β-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006;29:1337-44. (Pubitemid 44125932)
86. Th omas EL, Brynes AE, Hamilton G et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in nonalcoholic fatty liver disease. World J Gastroenterol 2006;12:5813-9.
87. Th amer C, Machann J, Stefan N et al. High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity 2007;15:531-8.
88. Schafer S, Kantartzis K, Machann J et al. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest 2007;37:535-43. (Pubitemid 46920190)
89. Cowin GJ, Jonsson JR, Bauer JD et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008;28:937-45.
90. Larson-Meyer DE, Newcomer BR, Heilbronn LK et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity 2008;16:1355-62. (Pubitemid 351770499)
91. Viljanen AP, Iozzo P, Borra R et al. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab 2009;94:50-5.
92. Kantartzis K, Th amer C, Peter A et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009;58:1281-8.
93. Kirk E, Reeds DN, Finck BN et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009;136:1552-60.
94. Lazo M, Solga SF, Horska A, et al., for the Fatty Liver Subgroup of the Look Ahead Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010;33:2156-63.
95. Wang R, Koretz R, Yee H. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003;115:554-9. (Pubitemid 37352802)
96. Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94. (Pubitemid 34717750)
97. Huang MA, Greenson JK, Chao C et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-81. (Pubitemid 40769044)
98. Tendler D, Lin S, Yancy WS Jr et al. Th e effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007;52:589-93. (Pubitemid 46202845)
99. Zelber-Sagi S, Kessler A, Brazowsky wsky E e t al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-44.
100. Harrison SA, Brunt EM, Fecht WJ et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial. Hepatology 2009;49:80-6.
101. Promrat K, Kleiner DE, Niemeier HM e t al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9.
102. Shojaee-Moradie F, Baynes KC, Pentecost C et al. Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia 2007;50:404-13.
103. Bonekamp S, Barone BB, Clark J et al. Th e effects of an exercise training intervention on hepatic steatosis [Abstract]. Hepatology 2008;48 (Suppl):806A.
104. Johnson NA, Sachinwalla T, Walton DW et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-12.
105. van der Heijden GJ, Wang ZJ, Chu ZD e t al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity 2010;18:384-90.
106. Marchesini G, Brizi M, Bianchi G et al. Metformin in non-alcoholic steatohepatitis . Lancet 2001;358:893-4. (Pubitemid 32900577)
107. Uygun A, Kadayifci A, Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Th er 2004;19:537-44. (Pubitemid 38387180)
108. Nair S, Diehl AM, Wiseman M et al. Metformin in the treatment of nonalcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Th er 2004;20:23-8. (Pubitemid 38938715)
109. Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90. (Pubitemid 40769045)
110. Loomba R, Lutchman G, Kleiner DE et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Th er 2009;29:172-82.
111. Shields WW, Th ompson KE, Grice GA et al. Th e effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot study. Th erap Adv Gastroenterol 2009;2:157-63.
112. Haukeland JW, Konopski Z, Eggesb HB et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44:853-60.
113. Idilman R, Mizrak D, Corapcioglu D et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Th er 2008;28 : 200-8.
114. Duseja A, Das A, Dhiman RK et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007;6:222-6.
115. Nar A, Gedik O. Th e effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009;46:113-8.
116. Omer Z, Cetinkalp S, Akyildiz M et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:18-23.
117. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR e t al. Improved nonalcoholic steatohepatitis aft er 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17. (Pubitemid 37221684)
118. Ratziu V, Giral P, Jacqueminet S et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Th erapy (FLIRT) Trial. Gastroenterology 2008;135:100-10. (Pubitemid 351916703)
119. Ratziu V, Charlotte F, Bernhardt C, et al., for the LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-53.
120. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307. (Pubitemid 44837778)
121. Aithal GP, Th omas JA, Kaye PV et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis . Gastroenterology 2008;135:1176-84.
122. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362 : 1675-85.
123. LincoffA, Wolski K, Nicholls S et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007;298:1180-8. (Pubitemid 47403104)
124. Hasegawa T, Yoneda M, Nakamura K et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with nonalcoholic steatohepatitis: a pilot study. Aliment Pharmacol Th er 2001;15:1667-72. (Pubitemid 32912411)
125. Harrison SA, Torgerson S, Hayashi P et al. Vitamin E and vitamin C treatment improves fibrosis is patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90. (Pubitemid 37448761)
126. Dufour JF, Oneta CM, Gonvers JJ et al. Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-43. (Pubitemid 44880031)
127. Sanyal AJ, Mofrad PS, Contos MJ et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis . Clin Gastroenterol Hepatol 2004;2:1107-15. (Pubitemid 40037642)
128. Yakaryilamz F, Guliter S, Savas B et al. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis, results of a pilot study. Intern Med J 2007;37:229-35. (Pubitemid 46457497)
129. Bjelakovic G, Gluud LL, Nikolova D et al. Meta-analysis: antioxidant supplements for liver disease-the Cochrane Hepato-Biliary Group. Aliment Pharmacol Th er 2010;32:356-67.
130. Lavine JE, Schwimmer JB, Van Natta ML e t al. for the Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68.
131. Miller ER III, Pastor-Barriuso R, Dalal D et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
132. Bjelakovic G, Nikolova D, Gluud LL et al. Mortality in randomized trials of antioxidant supplements of primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297:842-57 Review. Erratum in: JAMA. 2008 Feb 20;299(7):765--6. (Pubitemid 46333949)
133. Berry D, Wathen JK, Newell M. Bayesian model averaging in metaanalysis: vitamin E supplementation and mortality. Clin Trials 2009; 6:28-41.
134. Gerss J, Kopcke W. Th e questionable association of vitamin E supplementation and mortality-inconsistent results of different meta-analytic approaches. Cell Mol Biol 2009;55 (Suppl):OL1111-20.
135. Dietrich M, Jacques PF, Pencina MJ et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role? Atherosclerosis 2009;205:549-53.
136. Klein EA, Th ompson IM, Tangen CM et al. Vitamin E and the risk of prostate cancer. Th e selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011;306:1549-56.
137. Laurin J, Lindor KD, Crippin JS et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-7.
138. Leushner U, Lindenthal B, Herrman G et al. High-dose Ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:472-9.
139. Lindor KD, Kowldey KV, Heathcote EJ e t al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8. (Pubitemid 38337657)
140. Ratziu V, de Ledinghen V, Oberti F et al. A randomized controlled trial of high-dose ursogeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54:1011-9.
141. Capanni M, Calella F, Biagini MR e t al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Th er 2006;23:1143-51. (Pubitemid 43779354)
142. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Th er 2010;31:679-92.
143. Mathurin P, Hollebecque A, Arnalsteen L et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced liver disease. Gastroenterology 2009;137:532-40.
144. Mummadi RR, Kasturi KS, Chennareddygair S et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and metaanalysis . Clin Gastroenterol Hepatol 2008;6:1396-402.
145. Chavez-Tapia NC, Tellez-Avila FI, Barrientose-Gutierrez T et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database of Systematic Reviews 2010 Issue 1. Art No: CD007340. DOI:10:1002/14641858.
146. http://rethinkingdrinking.niaaa.nih.gov/IsYourDrinkingPatternRisky/ WhatsAtRiskOrHeavyDrinking.asp (Accessed 18 January 2012).
147. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47:1947-54. (Pubitemid 351945562)
148. Gunji T, Matsuhashi N, Sato H et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am J Gastroenterol 2009;104:2189-95.
149. Suzuki A, Angulo P, St Sauver J et al. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol 2007;102:1912-9. (Pubitemid 47301503)
150. Moriya A, Iwasaki Y, Ohguchi S et al. Alcohol consumption appears to protect against non-alcoholic steatohepatitis. Aliment Pharmacol Th er 2011;33:378-88.
151. Dixon JB, Bhathal PS, O ' Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100. (Pubitemid 32591518)
152. Cotrim HP, Freitas LA, Alves E et al. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 2009;21:969-72.
153. Dunn W, Brunt EM, Sanyal AJ et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease (NAFLD). Hepatology 50;390A:2009.
154. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012;32:22-9.
155. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;128:1287-92. (Pubitemid 38552793)
156. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-5. (Pubitemid 40250595)
157. Chalasani N. Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease. Hepatology 2005;41:690-5.
158. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006;44:466-71. (Pubitemid 44214886)
159. Lewis JH, Mortensen ME, Zweig S, et al., Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-63. (Pubitemid 350155527)
160. Horlander JC, Kwo PY, Cummings OW e t al. Atorvastatin for the treatment of NASH. Gastroenterology 2001;120 (Suppl):2767.
161. Gomer-Dominguez E, Gisbert JP, Moreno-Monteagudo A e t al. A pilot study of atorvastatin treatment in dyslipid, non-alcoholic fatty liver patients. Aliment Pharmacol Th er 2006;23:1643-7. (Pubitemid 43727474)
162. Antonopoulos S, Mikros S, Mylonopoulos M et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006;184:233-4. (Pubitemid 41721093)
163. Foster T, BudoffMJ, Saab S et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St. Francis Heart Study Randomized Clinical Trial. Am J Gastroenterol 2011; 106:71-7.
164. Athyros VG, Mikhalidis DP, Didangelos TP et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Curr Med Res Opin 2006;22:872-83.
165. Athyros VG, Tziomalos K, Gossios TD e t al. for the GREACE Study Collaborative Group. Lancet 2010;376:1916-22.
166. Ekstedt M, Franzen L, Mathiesen UL et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007;47:135-41. (Pubitemid 46817693)
167. Nelson A, Torres DM, Morgan AE et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebocontrolled trial. J Clin Gastroenterol 2009;43:990-4.
168. Brunt EM, Ramrakhiani S, Cordes BG et al. Concurrence of histological features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003;16:49-56. (Pubitemid 36152686)
169. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-42.
170. Petta S, Camma C, Di Marco V et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV. Liver Int 2011;31:507-11.
171. Eslam M, Aparcero R, Kawaguchi T et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Th er 2011;34:297-305.
172. Sorrentino P, Terracciano L, D ' Angelo S et al. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. J Gastroenterol 2010;45:1053-62.
173. Romero-Gomez M, Del Mar Viloria M, Andrade RJ e t al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41. (Pubitemid 40585366)
174. Reddy KR, Govindarajan S, Marcellin P et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2008;15:129-36.
175. Negro F, Clements S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy to hepatitis C. J Viral Hepat 2009;16:681-8.
176. Jacobson IM, McHutchison JG, Dusheiko G e t al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
177. Zeuzam S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
178. Bacon BR, Gordon SC, Lawtiz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
179. Poordad F, McCone J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;l:364-1195-1206.
180. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.
181. Garcia-Tsao G, Sanyal J, Grace ND, et al., for the Practice Guidelines Committee of the American Association for the Study of Liver Disease and the Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007;102:2086-102. (Pubitemid 47301543)
182. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
183. Schwimmer J, Deutsch R, Kahen T e t al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93. (Pubitemid 46393782)
184. Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-9. (Pubitemid 41233657)
185. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S et al. Th e natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-44.
186. Riley MR, Bass NM, Rosenthal P et al. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr 2005;147:839-42. (Pubitemid 41774844)
187. Patton H, Lavine JE, Van Natta ML, et al., for the NASH-CRN. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis (NASH). Gastroenterology 2008;135:1961-71.
188. Barlow SE, and the Expert Committee. Expert Committee Recommendations Regarding the Preventions, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report. Pediatrics 120;2007:S164-92.
189. Loomba R, Sirlin CB, Schwimmer JB e t al. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009;50:1282-93.
190. Alkhouri N, Carter-Kent C, Lopez R et al. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol 2011;9:150-5.
191. Nobili V, Parkes J, Bottazzo G et al. Performance of ELF serum markers in predicting serum fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009;136:160-7.
192. Kleiner DE, Brunt EM, Van Natta M, et al., Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
193. Carter-Kent C, Yerian LM, Brunt EM et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009;50:1113-20.
194. Ko JS, Yoon JM, Yang HR et al. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 2009;54:2225-30.
195. Nobili V, Marcellini M, Devito R et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006;44:458-65. (Pubitemid 44214885)
196. Nobili V, Manco M, Devito R et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48:119-28. (Pubitemid 351975537)
197. Barlow SE, Dietz WH. Management of child and adolescent obesity: summary and recommendations based on reports from pediatricians, pediatric nurse practitioners, and registered dietitians. Pediatrics 2002; 110:236-8. (Pubitemid 34728882)
198. Grundy SM, Cleeman JI, Daniels SR et al. American heart association. National heart, lung, and blood institute. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005;112:2735-52. (Pubitemid 41532612)